Loading clinical trials...

COMPLETEDNA

Internet-administered Interpersonal Psychotherapy for Depressive Symptoms

INDIGO - Internet-administered Interpersonal Psychotherapy for Depressive Symptoms

NCT04721678•Linkoeping University

Summary

The aim of the study is to test the efficacy of a treatment for depression based on interpersonal psychotherapy (IPT). The treatment will be accessed via an internet platform built for this study. A therapist will provide support weekly, as well as on-demand when needed. The treatment lasts for 10 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A diagnosis of Major depressive disorder (as indicated by the MINI 7.0 Neuropsychiatric interview) and/or depressive symptoms equal to or more severe than mild depression on the MADRS-S (equal to or above 13 points) and/or BDI (equal to or above 14 points).
•Age of at least 18 years old.
•Adequate ability to speak, write, and read Swedish.
•Internet access for the duration of the study.

Exclusion Criteria

•Ongoing substance abuse.
•Suicidal plans.
•A diagnosed personality syndrome (as diagnosed before the study by a licensed psychiatric healthcare professional).
•Other ongoing psychological treatment.
•Other severe psychiatric comorbidity that requires specialized care (e.g. anorexia nervosa, psychosis).
•Recent changes in psychotropic medication or planned changes during the initial treatment period.

Locations (1)

Department of Behavioral Sciences and Learning, Linköping University

Linköping, Östergötland County, Sweden

Key Dates

Start Date

January 22, 2021

Primary Completion Date

February 15, 2022

Completion Date

February 15, 2022

Last Updated

December 11, 2023

Enrollment

113

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

Interpersonal psychotherapy

BEHAVIORAL

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 11, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Internet-administered Interpersonal Psychotherapy for Depressive Symptoms

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults